Alpha-1-Antitrypsin-Deficiency in COVID-19

Universität des Saarlandes10 enrolled

Overview

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid19

Interventions

AAT( Alpha 1 Antitrypsin)DRUG

AAT administration based on clinical indication

Eligibility

Sex: ALLMin age: 18 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Infection with SARS-COV2 * Age over 18 years Exclusion Criteria: * Unability to consent * Invasive ventilation

Locations (1)

Saarland University

Homburg, Saarland, Germany

Outcomes

Primary Outcomes

Clinical course

Disease course such as death, need for ICU treatment, ventilatory support or deterioration are monitored

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.